CENTRAL TEXAS NEUROLOGY RESEARCH
CTNC has a tradition of excellence in clinical research, having participated in over 50 clinical trials. All of us at CTNC want our patients to be aware of our dedication to clinical research. Our physicians have extensive experience and are committed to advancing medical science through clinical research studies.
What is Clinical Research?
The National Institutes of Health defines “clinical research” as research conducted with human subjects (or on material of human origin such as tissues, specimens and cognitive phenomena) for which an investigator (or colleague) directly interacts with human subjects. Excluded from this definition are in vitro studies that utilize human tissues that cannot be linked to a living individual.Clinical research includes:
ACTIVE TRIALS: ENROLLING
ACTIVE TRIALS: ONGOINGEssential Tremors:
324-ETD-202
Phase 2 Double-blind, Randomized, Placebo-Controlled, Dose-Response Study of SAGE-324 for the Treatment of Essential Tremor
Status: Ongoing | Not Enrolling
Alzheimer's Disease:
J1G-MC-LAKC
Assessment of safety and efficacy measured by amyloid reduction of remternetug in early symptomatic Alzheimer's disease.
Status: Ongoing | Not Enrolling
Study Overview
I5T-MC-AACI
Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease.
Status: Ongoing | Not Enrolling
Study Overview
Parkinson's Disease:
IKT-148009-201
A Randomized, Double-Blind, Placebo-Controlled Trial of IkT-148009 in Untreated Parkinson's Disease
Status: Ongoing |Not EnrollingBP 39529
A Randomized, Double-Blind, Placebo-Controlled 52 week phase II Study to evaluate the efficacy of IV RO7046015 (PRX002) in participants with early Parkinson's Disease.
Status: Ongoing |Not Enrolling
Study Overview
BN42358
A Phase 2B, Randomized, Double-Blind, Placebo-Controlled, Multi-center study to evaluate the efficacy and safety of intravenous Prasinezumab in participants with early Parkinson's Disease.
Status: Ongoing |Not Enrolling
Study Overview
UPCOMING TRIALS:CLIN-10200-455
A Phase II, multi-center, randomized, double-blind, placebo-controlled Sequential Cohort Study to evaluate the efficacy and safety of two single doses of IPN10200 for the Treatment of Blepharospasm in Adults. Lundbeck 20303 A
A multi-site, randomized, double-blind, parallel-group, placebo-controlled trial to evaluate the efficacy, safety, and tolerability of 22 week oral treatment with LuAF28996 in participants with Parkinson's Disease. CVN-424-301
Phase 3 study in Parkinson's Disease patients with Motor Complications. NR-103A-01-IPS-3001
A Phase 3, randomized, double-blind, parallel-group, active-comparator, multi-center study to evaluate the safety of Proposed Biosimilar (MR-103A-01) Compared to OnabotullinumtoxinA (Botox) in Moderate to Severe Cervical Dystonia. A seamless Phase 2A-Phase 2B randomized double-blind placebo-controlled trial to evaluate the safety and efficacy of Benfotiamine in patients with early Alzheimer's Disease (BenfoTeam). AR1001-ADP3-US01
A Phase 3 double-blind, randomized, placebo-controlled, multi-center trial to evaluate the efficacy and safety of AR1001 over 52 weeks in participants with early Alzheimer's Disease. vent-02-102
A randomized, double-blind, placebo- controlled, phase 1B study of the NLRP3 inhibitor Vent-02 in patients with mild to moderate Parkinson's Disease. |
RESEARCH TEAM
Lenka Svedova
Nurse Practitioner Dr. Peckham Research Ext. 222 Kassandra Robinson
Research Coordinator Dr. Peery Ext. Learn More
Clinical Research Resources
|
Central Texas Neurology Consultants, PA ©2023
|
|